系统性硬化症中糖皮质激素处方实践:EUSTAR数据库分析
基于EUSTAR数据库2013年起纳入的9819例系统性硬化症患者,分析长期使用糖皮质激素的患病率、相关因素及处方实践的时间与国家差异。基线时34%(2769/8109)患者使用激素,中位剂量7.5 mg/天,使用者随访时间中平均25%处于用药状态。激素使用率从2013年36%逐渐降至2018年23%,国家间及国家内差异显著。
要点
- 基线时34%的系统性硬化症患者使用糖皮质激素,中位剂量7.5 mg/天。
- 随访超过1年的患者中,33%曾用药超过6个月,22%曾用药超过12个月。
- 激素使用率从2013年36%降至2018年23%,国家间及国家内差异显著。
核心结论
- 糖皮质激素在系统性硬化症中被广泛且长期处方,国家间及国家内差异显著,使用率逐渐下降。
研究设计与样本
- 纳入EUSTAR数据库自2013年1月起有访视记录的系统性硬化症患者9819例,分析激素使用患病率、使用特征、暴露时间及剂量。
- 采用多变量线性回归分析激素使用时长相关因素,探索时间趋势及招募国家间差异,缺失数据用链式方程多重插补。
主要发现
- 纳入患者中女性占85%,局限性皮肤型系统性硬化症(lcSSc)占73%,中位年龄58岁。
- 基线时34%(n=2769/8109)患者使用糖皮质激素,其中弥漫性皮肤型(dcSSc)为48%,lcSSc为29%,中位剂量7.5 mg/天。
- 激素使用者更多为男性、抗Scl-70阳性、dcSSc及病情更严重者。
- 激素使用者平均25%的随访时间(中位33.2个月)处于用药状态,亚组间无显著差异。
- 随访超过1年的患者中,33%(n=971/2959)曾用药超过6个月,22%(n=647/2959)曾用药超过12个月。
关键数值与推荐
- 多变量分析显示患者及疾病特征对激素暴露变异的解释力差(校正R²=0.06,P<0.001)。
- 激素使用率从2013年36%降至2018年23%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To estimate the prevalence of long-term exposure to glucocorticoids (GCs) and to identify factors associated with, and variations in prescribing practices over time and across recruiting countries. METHODS: We included patients with SSc having a visit recorded in the EUSTAR database from January 2013 onward. We analysed the prevalence and the main features of GCs users, their exposure to GCs over time, and their GCs dosages. Multivariable linear regression was used to analyse the factors identified as associated with GCs intake duration. Time trends, and variations in GCs utilization across recruiting countries were explored. Missing data were imputed using multiple imputation with chained equations. RESULTS: The 9819 patients included were mostly females (85%), the majority had lcSSc (73%), and the median age was 58 years. At baseline, 34% of patients (n = 2769/8109) (48% dcSSc vs 29% lcSSc) were on GCs, and the median dose was 7.5 mg/day. GCs users were more frequently males and anti-Scl70 positive, and more commonly had dcSSc and more severe disease. On average, GCs users spent 25% of their follow-up time (median 33.2 months) on GCs, with no significant between-subsets difference. Notably, 33% (n = 971/2959) and 22% (n = 647/2959) of patients followed up for >1 year had received GCs for >6 and >12 months, respectively. Multivariable analysis showed that patient and disease characteristics poorly explained the variability in GCs exposure (adjusted-R2 = 0.06, P < 0.001). GCs utilization varied within and across countries, and gradually decreased over time (36% in 2013 vs 23% in 2018). CONCLUSIONS: GCs are widely and long-term prescribed in SSc, with significant between-countries and within-country differences. A gradual decrease in their utilization has been observed.
引用
- Iudici M, Mongin D, Siegert E, et al. Glucocorticoids prescribing practices in systemic sclerosis: an analysis of the EUSTAR database. Rheumatology (Oxford). 2023. PMID: 36099040. doi:10.1093/rheumatology/keac533
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。